Drug Discovery & Development
Methods and Materials for Assaying Non-SCD1 Isoforms
WARF: P05362US
Inventors: James Ntambi, Makoto Miyazaki
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing useful tools for the discovery of SCD inhibitors.
Overview
Stearoyl-CoA desaturase (SCD) is the rate-limiting enzyme in the biosynthesis of monounsaturated fatty acids. Inhibitors of SCD may be useful therapeutics for diseases such as obesity and diabetes.
The Invention
UW-Madison researchers have developed useful tools for the discovery of SCD inhibitors. The invention consists of cDNAs for murine SCD2 and SCD3 and human SCD5, along with a stable mammalian cell line and yeast strain that express human SCD5. In addition, the invention includes SCD2, and SCD3 knockout and transgenic mice, as well as the targeting constructs used to generate the SCD1 and SCD3 transgenic mice.
Applications
- Useful in the development of SCD inhibitors
Key Benefits
- May lead to therapeutics for diseases such as obesity and diabetes
Tech Fields
For current licensing status, please contact Rafael Diaz at [javascript protected email address] or 608-960-9847